Company

Nurix Therapeutics, Inc.

Nurix Therapeutics develops targeted protein degradation medicines for oncology and autoimmune diseases.

About

Founded in 2012 in San Francisco, US, Nurix Therapeutics, Inc. uses targeted protein degradation technology to develop medicines for oncology and autoimmune diseases. It completed an IPO in July 2020 raising USD 209 mn and a Private Placement/Follow on in July 2022 raising USD 40 mn. Michael Rape is the founder and Arthur Sands is CEO. For 2023 it reported revenue of USD 76.99 mn and EBITDA of USD -147.53 mn. The company is at the Public stage.

4Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in